Prevents nausea and vomiting. ANDA 78776, held by Aurobindo Pharma. Ondansetron Hydrochloride.
As of Nov 16, 2026, ANDA 78776 (Ondansetron Hydrochloride), held by Aurobindo Pharma, was first approved by FDA on Nov 28, 2007, with 9 approved supplements and 0 published complete response letters.
Ondansetron oral solution is indicated for the prevention of nausea and vomiting associated with: highly emetogenic cancer chemotherapy, including cisplatin greater than or equal to 50 mg/m 2 initial and repeat courses of moderately emetogenic cancer chemotherapy radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen Ondansetron oral solution is also indicated for the prevention of postoperative nausea and/or vomiting.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 28, 2007 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Ondansetron HydrochlorideEQ 4MG BASE/5ML · solution;oral | Ondansetron Hydrochloride | Rx |
| Oct 23, 2025 | Supplement 19Labeling · Standard review | Approved | None posted |
| Jun 23, 2022 | Supplement 14Labeling · Standard review | Approved | None posted |
| Jun 23, 2022 | Supplement 15Labeling · Standard review | Approved | None posted |
| Mar 7, 2018 | Supplement 10Labeling · Standard review | Approved | None posted |
| Mar 27, 2017 | Supplement 9Labeling · Standard review | Approved | None posted |
| Dec 8, 2014 | Supplement 5Labeling · Standard review | Approved | None posted |
| Dec 8, 2014 | Supplement 7Labeling · Standard review | Approved | None posted |
| Oct 13, 2011 | Supplement 2Labeling | Approved | None posted |
| Jan 20, 2011 | Supplement 1Labeling | Approved | None posted |
| Nov 28, 2007 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters